{"filings":[{"id":2493162,"accession_number":"0001193125-26-368288","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-08-26T20:05:16+00:00","items":["8.01"],"status":"ready","headline":"LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial; triggers warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 500th subject in Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene + abemaciclib in ER+/HER2- ESR1-mutated metastatic breast cancer.","Milestone triggers exercisability of 23,031,494 Series A Common Warrants at $6.35/share from Dec 2025 private placement.","Full exercise would raise ~$146.2M; warrants expire 30 days after initial exercise date, no later than Nov 30, 2026.","Warrants exercisable cash or cashless if resale registration unavailable; initial exercise date set as of Aug 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2271517,"accession_number":"0001193125-26-352208","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-08-14T20:07:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeonaBio Q2 2026 net loss $19.0M; cash $51.1M; ELAINE-3 enrollment on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.0M ($0.80/sh) vs $7.0M ($1.78/sh) in Q2 2025; R&D spend up to $12.9M from $3.7M.","Cash, equivalents and investments $51.1M at June 30, 2026, down from $88.3M at Dec 31, 2025; ops cash burn $37.9M in quarter.","ELAINE-3 Phase 3 trial enrolled 495 patients; enrollment completion expected Q4 2026, topline data 2H 2027.","Up to $146M potential from cash-exercisable warrants from Dec 2025 financing to support development.","Board additions: Fred Callori, Natalie Holles, Peter Silverman effective May 5, 2026; John Fluke retired May 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1222088,"accession_number":"0001193125-26-279425","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-06-23T20:05:16+00:00","items":["5.07"],"status":"ready","headline":"LeonaBio stockholders elect three Class III directors, ratify EY as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kelly A. Romano, James A. Johnson, and Natalie Holles elected as Class III directors for three-year terms.","Ratification of Ernst & Young LLP as independent auditor for FY 2026 approved with 7,824,681 for, 10,708 against.","Advisory vote on executive compensation approved: 5,310,614 for, 24,139 against, 18,280 abstain.","Advisory vote favored every 3 years for future say-on-pay frequency (3,052,542 votes for 3 years vs 2,288,358 for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94133,"accession_number":"0001193125-26-211867","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeonaBio Q1 2026 net loss $32.9M ($1.73/share); cash burn $20.9M; ELAINE-3 enrollment target Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.9M ($1.73 per share) vs $9.1M ($2.34) in Q1 2025, driven by higher R&D spend.","Cash, equivalents and investments $67.7M at March 31, 2026, down from $88.3M at Dec 31, 2025.","R&D expenses $10.3M (up 139% YoY) due to Phase 3 ELAINE-3 lasofoxifene trial costs.","Expects to complete enrollment of Phase 3 ELAINE-3 in Q4 2026; topline data 2H 2027.","Appointed Fred Callori, Natalie Holles, Peter Silverman to Board; John Fluke Jr. retired."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106280,"accession_number":"0001193125-26-134097","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K/A","filed_at":"2026-03-31T23:59:59+00:00","items":["9.01","2.01","1.01"],"status":"ready","headline":"LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.","Sermonix reported ELAINE-3 cash expenditures of $14M (2023), $12M (2024), $5M (2025 through Dec 18).","LeonaBio expects $45M (2026) and $30M (2027) in ELAINE-3 cash spend; made ~$11M from Dec 18–31, 2025.","ELAINE-3 protocol amended to increase sample size from 500 to up to 600; enrollment completion targeted Q4 2026, topline data H2 2027.","License agreement grants LeonaBio exclusive rights to lasofoxifene for oncology outside Retained Territory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106283,"accession_number":"0001193125-26-126579","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LeonaBio reports FY2025 net loss $105.6M; acquires Phase 3 lasofoxifene, raises $90M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $105.6M ($24.70 per share) for FY2025 vs $96.9M loss in FY2024; R&D expenses rose to $85.6M on lasofoxifene license costs.","Cash and investments $88.3M at Dec 31, 2025, up from $51.3M year-end 2024; $90M private placement closed with potential $146M from warrant exercises.","Exclusive global license acquired for Phase 3 lasofoxifene (SERM) for ESR1-mutated metastatic breast cancer; ELAINE-3 enrollment completion expected 4Q2026, topline data 2H2027.","ATH-1105 Phase 2 proof-of-concept trial in ALS patients on track to initiate in 2H2026; Phase 1 data showed favorable safety and CNS penetration.","G&A expenses decreased to $16.7M from $26.1M, reflecting cost efficiencies; company renamed from Athira to LeonaBio in Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106282,"accession_number":"0001193125-26-116123","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"LeonaBio shareholders approve 2026 equity plan, 4x authorized share increase, and Sermonix warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 90M to 400M; total capital stock from 190M to 500M.","2026 Equity Incentive Plan approved: up to 5.7M shares initially, plus potential additions from lapsed 2020 Plan awards.","Stockholders approved issuance of 5,502,402 shares upon exercise of Sermonix pre-funded warrant.","Issuance to Sermonix and Perceptive Advisors exceeding 19.99% beneficial ownership also approved.","2026 Plan includes annual evergreen increase equal to the lesser of 5% of outstanding shares or Board-determined amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106281,"accession_number":"0001193125-26-008904","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.03","7.01","8.01","5.02","9.01"],"status":"ready","headline":"Athira Pharma renames to LeonaBio (LONA); lasofoxifene Phase 3 >50% enrolled; CFO gets new severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to LeonaBio effective Jan 9, 2026; ticker to LONA on Nasdaq starting Jan 12.","Phase 3 ELAINE-3 trial of lasofoxifene >50% enrolled; topline data expected mid-2027.","CFO Robert Renninger entered amended change in control severance agreement; base salary increased to $460,000.","Name change reflects Dec 2025 acquisition of lasofoxifene rights, with $90M upfront financing and potential additional $146M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122594,"accession_number":"0001193125-25-323692","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Athira Pharma raises ~$90M via PIPE and licenses lasofoxifene from Sermonix","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["PIPE gross proceeds ~$90M; investors include Commodore, TCGX, Perceptive; priced at $6.35/share with warrants.","Sermonix license grants exclusive rights to oral lasofoxifene outside Asia; $34.9M equity issued to Sermonix.","Milestone payments to Sermonix up to $100M; royalties from sub-single to low-single digit percentages.","Ligand agreement imposes separate milestones up to $21M and mid-single to low-double digit royalties.","Commodore and TCGX each get board designee if holding ≥5%; Company to seek resignation of two current directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122591,"accession_number":"0001193125-25-323786","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K/A","filed_at":"2025-12-18T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Athira Pharma licenses lasofoxifene rights, raises $90M in PIPE financing","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Licensed exclusive rights to oral lasofoxifene from Sermonix and Ligand for $34.9M in equity, plus monthly payments and up to $100M milestones.","PIPE raises ~$90M gross from Commodore, TCGX, Perceptive and others at $6.35/share with warrants exercisable after ELAINE-3 milestones.","Both PIPE and Sermonix closings expected December 23, 2025; proceeds for working capital, excluding debt repayment or stock redemption.","Commodore and TCGX each get board designation rights if holding 5%+; company to seek resignation of two current directors within 6 months.","Joseph Edelman (Perceptive) is a board member; Perceptive affiliates hold ~29% of Sermonix capital stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122593,"accession_number":"0001193125-25-269506","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma reports Q3 2025 net loss of $6.6M, cash at $25.2M; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.6M ($1.68 per share) vs $28.7M ($7.46 split-adjusted) in Q3 2024.","Cash and investments $25.2M as of Sept 30, 2025, down from $51.3M at Dec 31, 2024.","R&D expenses fell to $2.8M from $17.9M; G&A expenses $4.1M vs $7.6M year-over-year.","Company continues to explore strategic alternatives to maximize stockholder value; engaged Cantor Fitzgerald.","Phase 1 data for ALS candidate ATH-1105 showed favorable safety, dose-proportional PK, and CNS penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122592,"accession_number":"0001193125-25-229293","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":[],"status":"ready","headline":"Athira Pharma regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 2, 2025 that closing bid price was $1.00+ for ten consecutive days.","Compliance with Nasdaq minimum bid requirement is regained and the matter is closed.","Previously notified of deficiency on Oct 16, 2024 when stock fell below $1.00 for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139283,"accession_number":"0000950170-25-114093","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Athira Pharma to effect 10-for-1 reverse stock split on Sep 17 to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Sept 17 at 5pm ET; shares start trading split-adjusted on Sep 18 under ticker ATHA.","Every 10 pre-split shares convert to 1; authorized common shares reduced from 900M to 90M.","Purpose: increase share price to comply with Nasdaq's $1.00 minimum bid requirement.","Fractional shares paid in cash; CUSIP changes to 04746L203.","No action needed by book-entry or street-name holders; Computershare is exchange agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139282,"accession_number":"0000950170-25-105029","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.","Cash, equivalents and investments $29.8M as of June 30, 2025, down from $51.3M at Dec 31, 2024.","R&D expenses fell to $3.7M from $22.2M; G&A to $3.6M from $5.9M, reflecting cost reduction after LIFT-AD failure.","Phase 1 trial of ATH-1105 (ALS) showed favorable safety, dose-proportional PK, and CNS penetration; preparation for future ALS trial ongoing.","Company continues to explore strategic alternatives with Cantor Fitzgerald; fosgonimeton development paused."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156860,"accession_number":"0000950170-25-080234","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Athira shareholders approve reverse stock split at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class II director nominees elected: Joseph Edelman, John M. Fluke Jr., Grant Pickering.","Ratification of Ernst & Young as independent auditor approved (26,981,568 for).","Proposal to authorize reverse stock split approved (21,915,867 for, 4,835,818 against).","Board may set final split ratio from 5:1 to 20:1 in its discretion.","Quorum of 71.58% of shares present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156859,"accession_number":"0000950170-25-068020","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.","Net loss for Q1 2025 was $9.1M ($0.23 per share) vs $26.3M ($0.69 per share) in Q1 2024.","R&D expenses fell to $4.3M from $21.2M, driven by fosgonimeton program cuts after failed LIFT-AD trial.","ATH-1105 Phase 1 healthy volunteer study completed; full data expected 2H25, ALS patient dosing to begin late 2025.","Company exploring strategic alternatives with Cantor Fitzgerald after discontinuing fosgonimeton development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156858,"accession_number":"0000950170-25-054707","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Athira Pharma transfers to Nasdaq Capital Market; must regain $1 bid price by Oct 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved transfer from Nasdaq Global Select Market to Capital Market effective April 17, 2025.","Failed to meet $1 minimum bid price; granted 180-day grace period until October 13, 2025.","Must have bid price ≥ $1 for ten consecutive business days during grace period to regain compliance.","Seeking stockholder approval for reverse stock split at its 2025 annual meeting.","Stock continues trading under symbol 'ATHA' on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175263,"accession_number":"0000950170-25-029038","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.","Net loss $96.9M ($2.52 per share) vs $117.7M ($3.09 per share) in 2023; R&D expenses $70.7M, G&A $26.1M.","Legal expense $4.1M accrued for settlement with DOJ related to NIH grant.","ATH-1105 Phase 1 in 80 healthy volunteers completed with favorable safety; on track to dose ALS patients in 2025.","LIFT-AD Phase 2/3 of fosgonimeton missed endpoints; development paused; exploring strategic alternatives with Cantor Fitzgerald."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192211,"accession_number":"0000950170-24-123324","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q3 net loss $28.7M; LIFT-AD missed endpoints; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.7M ($0.75/sh) vs $33.0M ($0.87/sh) Q3 2023; cash $68.9M down from $147.4M at Dec 2023.","Fosgonimeton (ATH-1017) LIFT-AD Phase 2/3 missed primary and key secondary endpoints; development paused.","Exploring strategic alternatives with Cantor Fitzgerald; ATH-1105 Phase 1 healthy volunteers on track for year-end 2024.","R&D expenses $17.9M vs $27.2M; G&A $7.6M vs $7.8M; legal accrual $4.1M from DOJ investigation.","Plan to begin dosing ATH-1105 in ALS patients in 2025; preclinical data supports HGF-modulating mechanism."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192210,"accession_number":"0000950170-24-115592","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Athira Pharma receives Nasdaq bid price deficiency notice; stock below $1 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 16, 2024 for non-compliance with minimum bid price of $1.00.","Has 180 calendar days (until April 14, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.","May seek stockholder approval for reverse stock split if needed to cure deficiency.","Also plans to file new $300M shelf registration S-3 to replace expiring 2021 registration.","If not compliant by deadline, may transfer to Nasdaq Capital Market for additional 180-day cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192209,"accession_number":"0000950170-24-113210","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.","Lenington to provide consulting through Dec 31, 2024 at $41,666.67/month; equity vests during term.","CEO Mark Litton receives 325k RSUs + 325k options (strike $0.4257); VP Finance Renninger gets 37,077 RSUs + 37,077 options (strike $0.4499).","Retention awards vest 1/3 each on Dec 31, 2024, Jun 30, 2025, and Dec 31, 2025, subject to continued service.","2024 corporate goal achievement percentage automatically increased by 25 percentage points for certain executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208697,"accession_number":"0000950170-24-107031","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.","Annualized cost savings ~$13.4M; cash runway extended into Q1 2026.","CFO Andrew Gengos and COO Rachel Lenington terminated without cause, effective Oct 1, 2024.","VP Finance Robert Renninger appointed principal financial and accounting officer.","Focus shifts to ATH-1105 (oral HGF modulator) for ALS; Phase 1 completes by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208696,"accession_number":"0000950170-24-102788","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Athira's Phase 2/3 LIFT-AD trial of fosgonimeton misses primary endpoint; biomarker data mixed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint GST (p=0.70) and key secondary endpoints ADAS-Cog11 (p=0.35) and ADCS-ADL23 (p=0.61) not met; directionally favored fosgonimeton.","Prespecified subgroups (moderate AD, APOE4 carriers) showed numerically greater treatment effects; e.g., moderate AD ADAS-Cog11 delta -1.16 (p=0.39).","Biomarker p-Tau217 significantly reduced (p<0.01); NfL, GFAP, Aβ42/40 improved directionally.","Preliminary cash resources ~$75.1M as of Aug 31, 2024; ATH-1105 Phase 1 ongoing, completion expected by year-end 2024, ALS patients targeted for 2025.","Fosgonimeton well tolerated; SAEs similar to placebo; 22% early termination rate; full results to be presented at CTAD Oct 29-Nov 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208695,"accession_number":"0000950170-24-089281","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.","Net loss of $26.9M ($0.70 per share) for Q2 2024 vs. $29.6M ($0.78 per share) in Q2 2023.","R&D expenses $22.2M (up from $21.6M) driven by ATH-1105 Phase 1 trial; G&A down to $5.9M from $10.0M.","Topline data from Phase 2/3 LIFT-AD trial of fosgonimeton in Alzheimer's targeted for September 2024; full data at CTAD in October.","Phase 1 trial of oral ATH-1105 for ALS underway; first cohort completed, expected completion by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226427,"accession_number":"0000950170-24-065914","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Athira Pharma shareholders approve officer liability limitation charter amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Kosacz, Litton, and Panzara elected with For votes ranging from 77% to 82% of votes cast (excl. broker non-votes).","Ratification of Ernst & Young as auditor passed: 27,199,785 For, 59,069 Against, 99,855 Abstain.","Amendment to certificate of incorporation limiting officer liability approved: 19,365,835 For, 602,307 Against, 347,812 Abstain.","Broker non-votes were 7,042,755 on director election and charter amendment proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226426,"accession_number":"0000950170-24-061837","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Athira Pharma obtains preliminary approval for derivative lawsuit settlement with governance reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court preliminary approval on May 3, 2024; final hearing set for July 18, 2024.","Settlement requires Athira to adopt corporate governance reforms and pay lead plaintiffs' attorney's fees, expenses, and service awards.","Derivative actions Bushansky v. Kawas and Houlihan v. Kawas covered by the Stipulation of Settlement dated March 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226425,"accession_number":"0000950170-24-060452","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.","Cash and investments $122.1M as of March 31, 2024, down from $147.4M at year-end 2023.","LIFT-AD Phase 2/3 topline data for fosgonimeton in Alzheimer's expected H2 2024; enrollment complete.","IND submitted for ATH-1105 (ALS); first-in-human study expected to start Q2 2024.","Appointed Javier San Martin, M.D. as Chief Medical Officer in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245436,"accession_number":"0000950170-24-018764","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Athira Pharma FY2023 net loss $117.7M; LIFT-AD enrollment complete; data H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $117.7M ($3.09/sh) vs $95.6M ($2.53/sh) in FY2022; R&D spend rose to $93.8M.","Cash and investments $147.4M as of Dec 31, 2023, down from $245.2M at end of 2022.","Phase 2/3 LIFT-AD trial (fosgonimeton) enrollment completed (~315 pts); topline data expected H2 2024.","First-in-human study of ATH-1105 for ALS on track to initiate in H1 2024.","Adopted 2024 Inducement Plan reserving 750,000 shares; appointed COO/Chief Dev Officer and Chief People Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245435,"accession_number":"0000950170-24-002686","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Athira reports $147.4M cash, completes LIFT-AD enrollment, CMO Moebius retiring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and investments of ~$147.4M as of Dec 31, 2023.","Completed enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer's; topline data expected H2 2024.","Plans to initiate first-in-human studies of ATH-1105 for ALS in H1 2024.","CMO Hans Moebius retired effective Jan 5, 2024; will serve as Senior Scientific Advisor through March 31 transition period.","Over 60 patients continue fosgonimeton treatment beyond 18 months in open-label extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262919,"accession_number":"0000950170-23-062045","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q3 net loss widens to $32.7M, cash at $172.9M; LIFT-AD enrollment expected Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.7M ($0.87/share) vs $20.2M ($0.53/share) in Q3 2022; R&D expenses up $10.2M to $27.2M.","Cash, cash equivalents and investments at $172.9M as of Sept 30, down from $245.2M at Dec 31, 2022; operating cash burn $74.5M YTD.","Phase 2/3 LIFT-AD trial enrollment for fosgonimeton expected complete by Q1 2024; topline data anticipated in H2 2024.","ATH-1105 (oral ALS candidate) IND-enabling studies ongoing; first-in-human study expected in H1 2024.","New preclinical fosgonimeton data to be presented at Neuroscience 2023 (Nov 11-15) in Washington, D.C."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280104,"accession_number":"0000950170-23-041320","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q2 net loss $29.6M ($0.78/sh); cash $196.3M; LIFT-AD results H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.6M ($0.78/sh) vs $24.3M ($0.65/sh) in Q2 2022; R&D spend rose to $21.6M.","Cash, cash equivalents and investments $196.3M at June 30, 2023, down from $245.2M at Dec 31, 2022.","Completed end-of-Phase 2 FDA meeting for fosgonimeton; LIFT-AD topline expected H2 2024.","Appointed Andrew Gengos as CFO and Chief Business Officer.","IND-enabling studies for ATH-1105 continue; first-in-human studies targeted H1 2024 for ALS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298611,"accession_number":"0001193125-23-149921","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Athira Pharma appoints Andrew Gengos as CFO and CBO; Glenna Mileson retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Gengos appointed CFO and CBO effective May 18, 2023, replacing Glenna Mileson who is retiring after eight years.","Gengos receives $465,000 base salary, 40% bonus target, 400,000 stock options, and 10,000 RSUs tied to LIFT trial milestones.","Mileson will remain as transitional employee until June 16, 2023, then may serve as consultant at $3,500/month for up to 10 hours.","Stockholders elected Class III directors Kelly Romano and James Johnson; ratified Ernst & Young as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298610,"accession_number":"0000950170-23-021239","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q1 net loss $27.8M; focuses Alzheimer's trial on 40 mg dose","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.8M ($0.73/share) vs $21.0M ($0.56) in Q1 2022; cash $219.9M.","Phase 2/3 LIFT-AD trial to focus on 40 mg fosgonimeton; 70 mg arm discontinued.","Open-label extension extended to up to 30 months; >85% enrollment from prior trials.","ATH-1105 preclinical data in ALS shows prolonged survival and improved motor function; IND-enabling work for 2024 first-in-human.","End of Phase 2 meeting with FDA scheduled for summer 2023; timeline update expected."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318822,"accession_number":"0000950170-23-009483","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma reports FY2022 net loss of $95.6M ($2.53/sh); cash $245.2M; $10M legal settlement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $95.6M ($2.53 EPS) vs $54.9M ($1.49 EPS) in 2021; R&D spend rose 44% to $61.5M.","Cash, equivalents and investments $245.2M at Dec 31, 2022, vs $319.7M year earlier.","Recorded $10M legal settlement expense for securities class action; subject to court approval.","Targeting LIFT-AD Phase 2/3 enrollment completion mid-2023, topline data early 2024.","ATH-1105 (ALS) IND-enabling studies ongoing; Phase 1 expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318821,"accession_number":"0000950170-23-000364","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Athira enters ATM stock offering; reports ~$245.2M cash as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Cantor Fitzgerald & BTIG for at-the-market offering of common stock.","Agents to receive 3.0% of gross proceeds; Company has no obligation to sell any shares.","Preliminary cash, equivalents and investments total ~$245.2M as of Dec 31, 2022 (unaudited).","Shares to be issued under effective shelf registration statement on Form S-3 (File No. 333-261073).","Prospectus supplement dated Jan 6, 2023 filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337051,"accession_number":"0000950170-22-025442","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Athira Pharma amends bylaws for SEC Rule 14a-19 compliance and advance notice updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended and restated bylaws effective November 15, 2022.","Changes comply with new SEC Rule 14a-19 (universal proxy) and enhance advance notice for stockholder proposals and nominations.","Bylaws updated for recent Delaware General Corporation Law amendments on stockholder meetings.","Modifications to officer appointments, board committee procedures, and forum selection clause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337050,"accession_number":"0000950170-22-024464","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma reports Q3 net loss of $20.2M; LIFT-AD interim analysis supports continuation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.2M ($0.53/shr) for Q3 2022 vs $15.7M ($0.42) in Q3 2021; cash $260.0M at Sep 30, 2022.","R&D expenses $17.0M (up from $10.7M YoY) driven by clinical trial and personnel costs.","LIFT-AD interim analysis supports continuation; DMC determined <150 more patients needed for adequate power on primary endpoint.","Expects LIFT-AD enrollment completion mid-2023; topline data early 2024.","ACT-AD Phase 2 data showed statistically significant improvement in NfL biomarker in patients not on background therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337049,"accession_number":"0000950170-22-019592","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Athira gets positive interim analysis for Alzheimer's drug fosgonimeton, study continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent data monitoring committee recommended continuation of LIFT-AD after unblinded interim analysis.","Adding fewer than 150 patients (total <300 with no background therapy) will power study for primary endpoint.","Interim analysis in ~100 patients not on background therapy corroborated prior ACT-AD Phase 2 findings.","Company targets enrollment completion mid-2023 and topline data in early 2024.","CEO cites strong balance sheet to execute through key data readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354415,"accession_number":"0000950170-22-017392","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira reports Q2 net loss $24.3M; ACT-AD Phase 2 Alzheimer's trial missed primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.3M ($0.65/share) vs $14.0M ($0.38/share) in Q2 2021; cash $282.2M.","ACT-AD Phase 2 trial of fosgonimeton did not meet primary endpoint (P300 latency).","Monotherapy subgroup showed ADAS-Cog11 improvement of -3.3 points vs placebo (not significant).","Statistically significant reduction in plasma NfL biomarker in monotherapy subgroup (p=0.018).","LIFT-AD Phase 3 enrollment ongoing; over 300 patients enrolled as of report date."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372380,"accession_number":"0000950170-22-011935","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Athira Phase 2 ACT-AD misses primary endpoint; monotherapy subgroup shows cognitive benefit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint ERP P300 latency not statistically significant in full mITT population (-6.02 ms vs placebo).","Pre-specified subgroup: combination with AChEIs diminished fosgonimeton effect; post hoc monotherapy showed ERP P300 improvement of -28 ms and ADAS-Cog11 -3.3 points.","Fosgonimeton well tolerated; no treatment-related SAEs or deaths; injection site reaction most common AE.","Study enrolled 77 patients; 14% early termination rate; results to inform ongoing Phase 3 LIFT-AD (NCT04488419).","Management plans to seek regulatory advice on potential adaptations to LIFT-AD based on these findings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372379,"accession_number":"0001193125-22-158630","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Athira shareholders elect all three Board nominees; Kayne's director candidates defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board nominees Edelman, Fluke, and Pickering each received >17M votes; Kayne and Bickerstaff received ~8.8M and ~9.0M.","Ratification of Ernst & Young as auditor passed with 32.8M votes for, 119K against.","Stockholder proposal to repeal certain bylaws failed with 11.1M for, 18.0M against.","Approximately 87.7% of outstanding shares voted at the May 19, 2022 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372378,"accession_number":"0000950170-22-009670","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q1 net loss $21.0M; topline ACT-AD Phase 2 data by end of 2Q22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.0M ($0.56/share) vs $8.9M ($0.25/share) in Q1 2021; R&D expense $14.5M, up from $7.4M.","Cash, equivalents & investments $301.2M at March 31, 2022 vs $319.7M at December 31, 2021.","Topline ACT-AD Phase 2 data in mild-to-moderate Alzheimer's expected by end of Q2 2022.","LIFT-AD Phase 3 enrollment target increased to ~420 patients; completion expected in Q3 2022.","Dosed first patient in SHAPE Phase 2 trial for Parkinson's disease dementia and Dementia with Lewy bodies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391230,"accession_number":"0000950170-22-004547","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira reports FY2021 net loss $54.9M; ACT-AD Phase 2 data on track for Q2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.9M ($1.49/share) vs $19.9M in 2020; R&D spend $42.8M, up from $13.3M.","Cash & investments $319.7M as of Dec 31, 2021; cash used in ops $43.1M in 2021.","Topline ACT-AD Phase 2 Alzheimer's data expected Q2 2022; LIFT-AD Phase 3 enrollment to complete Q3 2022.","First patient dosed in SHAPE Phase 2 in Parkinson's dementia / DLB; ATH-1020 Phase 1 initiated.","Appointed Grant Pickering and Dr. Michael Panzara to Board; expanded management team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391229,"accession_number":"0001193125-22-080027","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Athira Pharma appoints Dr. Michael Panzara to board effective March 18, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Panzara, CMO at Wave Life Sciences, appointed Class I director with term expiring at 2024 annual meeting.","He brings over 20 years CNS drug development experience, including leadership at Sanofi Genzyme and Biogen.","Compensation includes initial stock option grant; no transactions with the company or its affiliates.","Press release notes his role in global regulatory approvals of MS drugs LEMTRADA, AUBAGIO, and TYSABRI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391228,"accession_number":"0001193125-22-023358","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Athira appoints Grant Pickering director; CEO gets $543k salary, 50% bonus target, enhanced severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant Pickering (CEO of Vaxcyte) appointed to board effective Jan 27, 2022.","CEO Mark Litton salary raised from $510k to $543,400; bonus target increased from 40% to 50%.","Amended severance: 12 months base salary (non-CIC) or 18 months salary + 150% bonus (CIC), plus equity acceleration.","Director compensation policy amended: $35k/year cash retainer; initial option grant 27,742 shares vesting monthly over 3 years; annual option grant 13,871 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409411,"accession_number":"0000950170-21-004081","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q3 net loss $15.7M; ACT-AD trial enrollment completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.7M ($0.42 per share) vs $8.5M loss in Q3 2020; R&D spend $10.7M.","Cash, cash equivalents and investments $339.4M as of Sept 30, 2021, up from $268.2M at Dec 31, 2020.","Completed enrollment in Phase 2 ACT-AD trial (77 subjects); topline data expected H1 2022.","LIFT-AD Phase 2/3 actively recruiting; topline data expected by end of 2022.","SHAPE Phase 2 trial (Parkinson's dementia) anticipated to initiate by end of 2021; IND for ATH-1020 expected by end of 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409410,"accession_number":"0001193125-21-304002","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2021-10-21T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CEO Leen Kawas resigns after special committee finds she altered images in doctoral research; Mark Litton appointed CEO.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Special committee concluded Dr. Kawas altered images in her 2011 dissertation and at least four research papers co-authored as a WSU graduate student.","Mark Litton, Ph.D., MBA, appointed President and CEO and to the board; Rachel Lenington, MBA, appointed COO, effective Oct 18, 2021.","Severance: Kawas receives lump sum of $510,000 plus COBRA reimbursement for up to 18 months; retains options for 363,535 shares.","ATH-1017 patent does not cite altered-image papers; Phase 1a/b trial results reaffirmed as statistically significant per independent audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428330,"accession_number":"0001564590-21-044631","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Athira Pharma Q2 net loss $14.0M; advances Alzheimer's trials; open label extension initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.0M ($0.38/sh) vs $2.0M loss in Q2 2020; R&D expenses $12.0M (up from $1.7M).","Cash and investments $349.9M as of June 30, 2021, up from $268.2M at year-end 2020.","Open label extension started for LIFT-AD and ACT-AD trials; topline data ACT-AD by H1 2022, LIFT-AD by end 2022.","Phase 2 trial of ATH-1017 for Parkinson's disease dementia targeted to start by end 2021; IND for ATH-1020 by end 2021.","COO Mark Litton assumes day-to-day leadership; board chair Tadataka Yamada died; Kelly Romano appointed chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428329,"accession_number":"0001193125-21-239806","cik":1620463,"company_name":"LeonaBio, Inc.","ticker":"LONA","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Athira Pharma board chair Tadataka Yamada dies; Kelly Romano named new chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Tadataka Yamada, Chair of Board since Jan 2020, died unexpectedly on Aug 4, 2021.","Board appointed Kelly A. Romano as new Chair and Barbara Kosacz as Chair of Compensation and Nominating Committees.","Romano brings 30+ years of executive experience, previously president at UTC Building & Industrial Systems.","Yamada was a venture partner at Frazier Healthcare, co-founder of several biotechs, and former exec at Takeda and Gates Foundation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":93935140.67278288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}